





EXHIBIT O


Infringement Of U.S. Patent No. 11,408,033 Patent By Foresight's Solid Tumor Recurrence Test

'033 Patent Claim Language	Infringement Support
1. A method for analyzing a nucleic acid sample obtained from an individual, comprising:	The Foresight Diagnostics Solid Tumor Recurrence Test performs a method for analyzing a nucleic acid sample obtained from an individual.  Source: https://foresight-dx.com/partnership
(a) producing, with the aid of a computer processor, a plurality of capture probes, wherein said plurality of capture probes hybridize to a plurality of polymorphisms, wherein said plurality of polymorphisms are in sequences encoding genes with known biomedically interpretable	The Foresight Diagnostics Solid Tumor Recurrence test utilizes computer processors to produce capture probes hybridized to polymorphisms. The test sequences both tumor and germline DNA (to provide a reference) in order to identify phased variants that are present in the tumor sample. The polymorphisms are in sequences encoding genes with known biomedically interpretable variants, and are extracted from a database of polymorphisms obtained from the patient, and are observed in a population of one sample previously taken from the patient.

'033 Patent Claim Language	Infringement Support												
variants, and wherein said plurality of polymorphisms are based on or extracted from one or more databases of polymorphisms, and are observed in a population of one or more samples,	 Source: Kurtz, Fig. 7b <table><tr><th>PhasED-Seq (Foresight Diagnostics)</th><th>Hybrid capture-based NGS</th><th>PVs, SNVs</th><th>Baseline: tumor or plasma MRD/monitoring: plasma</th><th>Tumor-informed</th><th>< 0.0001% TF</th></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr></table> Chen K et al., MolDiag&Ther 2021 Source: BloodPac annual meeting slides (BloodPac slides, attached hereto as Exhibit L); Chen, et al., Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors, MolDiag&Ther (2021) at Table 1 (hereinafter “Chen,” attached hereto as Exhibit M). In addition, the Foresight Diagnostics Solid Tumor Recurrence test tracks clinically	PhasED-Seq (Foresight Diagnostics)	Hybrid capture-based NGS	PVs, SNVs	Baseline: tumor or plasma MRD/monitoring: plasma	Tumor-informed	< 0.0001% TF						
PhasED-Seq (Foresight Diagnostics)	Hybrid capture-based NGS	PVs, SNVs	Baseline: tumor or plasma MRD/monitoring: plasma	Tumor-informed	< 0.0001% TF								


'033 Patent Claim Language	Infringement Support
	relevant polymorphisms that are in genes with known biomedically interpretable variants, wherein said plurality of polymorphisms are based on or extracted from one or more databases of polymorphisms, and are observed in a population of one or more samples:  Source: https://foresight-dx.com/partnership
(b) contacting said nucleic acid sample with said plurality of capture probes produced in (a)	The method of conducting the Foresight Diagnostics Solid Tumor Recurrence test involves contacting nucleic acid samples with capture probes.

'033 Patent Claim Language	Infringement Support
	b  Source: Kurtz, Fig. 7b PhasED-Seq (Foresight Diagnostics) Hybrid capture-based NGS PVs, SNVs Baseline: tumor or plasma MRD/monitoring: plasma Tumor-informed < 0.0001% TF Chen K et al., MolDiag&Ther 2021 BloodPac slides; Chen at Table 1
(c) conducting a sequencing assay on a subset of nucleic acid molecules generated from said nucleic acid sample in step (b) to yield a result comprising a nucleic acid sequence, thereby analyzing said nucleic acid sample; and	The Foresight Diagnostics Solid Tumor Recurrence test conducts a sequencing assay on a subset of nucleic acids generated from the plasma DNA sample.

'033 Patent Claim Language	Infringement Support
	 Source: Kurtz, Fig. 7b
(d) repeating steps (b)-(c) on a subsequently obtained biological sample from said individual.	The Foresight Diagnostics Solid Tumor Recurrence test repeats the sequencing assay performed multiple times over time. For example, Kurtz at Extended Fig. 10d shows the tracking and identification of the presence or absence of the PVs in subsequently obtained samples.

'033 Patent Claim Language

Infringement Support




Source: Kurtz, Extended Fig. 10d.

The results of the additional tracking and whether the PVs were observed or not in the subsequently obtained plasma sample may be reported in a biomedical report.

'033 Patent Claim Language

Infringement Support



Source: ASCO Meeting 2021: Abstract #8518: Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer, David M. Kurtz, et al. (hereinafter "Kurtz Poster," attached hereto as Exhibit K).

Additionally, the Foresight website indicates the use of time-based reporting and monitoring:


'033 Patent Claim Language	Infringement Support
	 Source: https://foresight-dx.com/technology
2. The method of claim 1, further comprising, subsequent to (c), generating a biomedical report that includes biomedical information of said individual, which biomedical information is indicative of said result.	The Foresight Diagnostics Solid Tumor Recurrence test generates a biomedical report that includes biomedical information, including whether the polymorphisms identified in the prior sequencing of the plasma samples is or is not present. For example, Kurtz shows in Extended Fig. 10d whether the tracked polymorphisms were detected or not detected in the subsequently analyzed plasma samples from additional time points.

'033 Patent Claim Language	Infringement Support																																					
	d <table><thead><tr><th rowspan="2">Case</th><th rowspan="2">Stage</th><th rowspan="2">No. of PVs Tracked</th><th colspan="2">Time of Diagnosis</th></tr><tr><th>Before Diagnosis</th><th>After Diagnosis</th></tr></thead><tbody><tr><td>BRCA001</td><td>IIIB</td><td>14</td><td> </td><td> </td></tr><tr><td>LUP502</td><td>IB</td><td>116</td><td> </td><td> </td></tr><tr><td>LUP503</td><td>IA</td><td>223</td><td> </td><td> </td></tr><tr><td>LUP649</td><td>IB</td><td>120</td><td> </td><td> </td></tr><tr><td>LUP831</td><td>IIIB</td><td>82</td><td> </td><td> </td></tr><tr><td>LUP814</td><td>IIIB</td><td>622</td><td> </td><td> </td></tr></tbody></table> Patient Samples Control Samples not detected PhasED-Seq detected CAPP-Seq detected false positive PhasED-Seq detected CAPP-Seq not detected Source: Kurtz, Extended Fig. 10d.	Case	Stage	No. of PVs Tracked	Time of Diagnosis		Before Diagnosis	After Diagnosis	BRCA001	IIIB	14			LUP502	IB	116			LUP503	IA	223			LUP649	IB	120			LUP831	IIIB	82			LUP814	IIIB	622		
Case	Stage				No. of PVs Tracked	Time of Diagnosis																																
		Before Diagnosis	After Diagnosis																																			
BRCA001	IIIB	14																																				
LUP502	IB	116																																				
LUP503	IA	223																																				
LUP649	IB	120																																				
LUP831	IIIB	82																																				
LUP814	IIIB	622																																				
3. The method of claim 2, wherein said biomedical information of said individual is predictive, prognostic, or diagnostic of one or more biomedical features selected from the group consisting of disease state, efficacy of a drug therapy, prediction of optimal drug dosage, recommendation of one or more therapies, and recommendation of a course of treatment of a disease.	The Foresight Diagnostics Solid Tumor Recurrence tests utilizes cfDNA obtained from plasma DNA obtained from individuals and reports out the presence or absence of cancer (disease state) as well as a recommendation on therapy.																																					

'033 Patent Claim Language	Infringement Support																																			
	d <table border="1"><thead><tr><th>Case</th><th>Stage</th><th>No. of PVs Tracked</th><th>Before Diagnosis</th><th>After Diagnosis</th></tr></thead><tbody><tr><td>BRCA001</td><td>IIIB</td><td>14</td><td>14</td><td>14</td></tr><tr><td>LUP502</td><td>IB</td><td>116</td><td>116</td><td>116</td></tr><tr><td>LUP503</td><td>IA</td><td>223</td><td>223</td><td>223</td></tr><tr><td>LUP649</td><td>IB</td><td>120</td><td>120</td><td>120</td></tr><tr><td>LUP831</td><td>IIIB</td><td>82</td><td>82</td><td>82</td></tr><tr><td>LUP814</td><td>IIIB</td><td>622</td><td>622</td><td>622</td></tr></tbody></table> Time of Diagnosis Before Diagnosis : After Diagnosis Patient Samples Control Samples not detected false positive PhasED-Seq detected CAPP-Seq detected PhasED-Seq detected CAPP-Seq not detected	Case	Stage	No. of PVs Tracked	Before Diagnosis	After Diagnosis	BRCA001	IIIB	14	14	14	LUP502	IB	116	116	116	LUP503	IA	223	223	223	LUP649	IB	120	120	120	LUP831	IIIB	82	82	82	LUP814	IIIB	622	622	622
Case	Stage	No. of PVs Tracked	Before Diagnosis	After Diagnosis																																
BRCA001	IIIB	14	14	14																																
LUP502	IB	116	116	116																																
LUP503	IA	223	223	223																																
LUP649	IB	120	120	120																																
LUP831	IIIB	82	82	82																																
LUP814	IIIB	622	622	622																																
	Source: Kurtz, Extended Fig. 10d. The results of the additional tracking and whether the PVs were observed or not in the subsequently obtained plasma sample may be reported in a biomedical report.																																			

'033 Patent Claim Language

Infringement Support



Source: Kurtz Poster.

vs


Foresight Diagnostics


✓ Best-in-class sensitivity at all time-points


✓ Detects relapse **200+ days prior** to clinical relapse⁽¹⁾


✓ Identifies relapse when **disease burden is low** and **probability of cure is higher**


✓ Identifies the majority of patients **in need of additional therapy**


'033 Patent Claim Language	Infringement Support
	Source: https://foresight-dx.com/technology
4. The method of claim 1, wherein said plurality of polymorphisms comprise one or more insertions, deletions, structural variant junctions, variable length tandem repeats, single nucleotide mutations, or a combination thereof.	The Foresight Diagnostics Solid Tumor Recurrence test tracks single nucleotide mutations.  Source: https://foresight-dx.com/partnership
5. The method of claim 1, wherein said sequences encoding genes with known biomedically interpretable variants comprise a plurality of sequences encoding genes associated with cancer.	The Foresight Diagnostics Solid Tumor Recurrence test tracks single nucleotide mutations that are in genes with known biomedically interpretable variants, specifically, oncogenic and clinically relevant SNVs.

'033 Patent Claim Language	Infringement Support
	 Source: https://foresight-dx.com/partnership
6. The method of claim 1, further comprising identifying the presence or absence of said plurality of polymorphisms in said nucleic acid sample.	The Foresight Diagnostics Solid Tumor Recurrence test issues a report regarding the identification the presence or absence of the detected PVs in the second nucleic acid sample obtained from plasma. For example, Kurtz at Extended Fig. 10d shows the tracking and identification of the presence or absence of the PVs in subsequently obtained samples.

'033 Patent Claim Language	Infringement Support
	d  Source: Kurtz, Extended Fig. 10d.
7. The method of claim 2, wherein said identifying comprises observing an allele frequency of said plurality of polymorphisms.	The Foresight Diagnostics Solid Tumor Recurrence test calculates the variant allele fraction (VAF) for the observed phased variants detected in the sample. For example, the Supplementary Methods section of Kurtz describes the procedure for the “Identification of phased variants and allelic quantitation.” Kurtz states “[t]o calculate the VAF of each PV, we calculated a numerator representing the number of DNA molecules containing a PV of interest over a denominator representing the total number of DNA molecules that covered the genomic region of interest. That is, the numerator is simply the total number of deduplicated read pairs that contain a given PV while the denominator is the number of read-pairs that span the genomic locus of a given PV.” Source: Kurtz, Supplementary Methods at 8.
9. The method of claim 1, wherein said	The plurality of capture probes are conjugated to beads:


'033 Patent Claim Language	Infringement Support
plurality of capture probes are conjugated to beads.	 The diagram, labeled 'b', illustrates a personalized medicine workflow. It begins with a red human figure. A horizontal timeline shows 'Diagnosis of malignancy' (black dot), 'Treatment' (yellow bar), and 'Subsequent TIME POINT' (black dot). Below 'Diagnosis of malignancy', two test tubes are shown: 'Germline DNA' (red) and 'Tumor biopsy DNA' (blue). Below 'Subsequent TIME POINT', a test tube labeled 'Plasma DNA' (red) is shown. Arrows lead from the DNA samples to sequencing steps: 'I-seq' (red arrow) and 'WGS' (yellow arrow) lead from Germline DNA to 'PV discovery' (yellow arrow), which leads to 'Personalized selector design' (yellow arrow). 'Personalized selector design' is circled in red. 'I-seq' (green arrow) and 'WGS' (green arrow) lead from Tumor biopsy DNA to 'Personalized selector sequencing' (green arrow), which is circled in red. 'Personalized selector sequencing' leads to 'Personalized PV monitoring' (green arrow). The diagram shows the integration of germline and tumor DNA for diagnosis and treatment, and plasma DNA for subsequent monitoring. Source: Kurtz, Fig. 7b
11. The method of claim 1, wherein said nucleic acid sample obtained from said individual is from a body fluid, cell, skin, tissue, organ, or combination thereof.	The Foresight Diagnostics Solid Tumor Recurrence tests utilizes samples isolated from an individual's germline DNA, tumor biopsy DNA, and plasma DNA.

'033 Patent Claim Language	Infringement Support
	 The diagram, labeled 'b', illustrates a personalized medicine workflow. It begins with a red human figure. A horizontal timeline shows 'Diagnosis of malignancy' (black dot), 'Treatment' (orange bar), and 'Subsequent TIME POINT' (black dot). Below 'Diagnosis of malignancy', two DNA samples are shown: 'Germline DNA' (represented by a test tube) and 'Tumor biopsy DNA' (represented by a cluster of cells). Below 'Subsequent TIME POINT', 'Plasma DNA' is shown (represented by a test tube). A red circle highlights the 'Plasma DNA' sample. Arrows indicate the flow of information: from 'Germline DNA' and 'Tumor biopsy DNA' through 'I-seq' and 'WGS' to 'PV discovery', leading to 'Personalized selector design' (represented by a DNA helix with a 'B' marker). From 'Plasma DNA', an arrow leads to 'Personalized selector sequencing' (represented by a DNA helix with a 'B' marker), which then leads to 'Personalized PV monitoring'. Source: Kurtz, Fig. 7b
12. The method of claim 11, wherein said body fluid is blood plasma.	The Foresight Diagnostics Solid Tumor Recurrence tests utilizes samples isolated from an individual's germline DNA, tumor biopsy DNA, and plasma DNA.

'033 Patent Claim Language	Infringement Support
	 Source: Kurtz, Fig. 7b
13. The method of claim 12, wherein said plasma sample is obtained from said individual at a first time point, and further comprising, subsequent to (c), using said capture probes to generate an additional subset of nucleic acid molecules from an additional nucleic acid sample isolated from an additional plasma sample obtained from said individual at an additional time point different from said first time point.	The Foresight Diagnostics Solid Tumor Recurrence test repeats the sequencing assay performed multiple times over time. For example, Kurtz at Extended Fig. 10d shows the tracking and identification of the presence or absence of the PVs in subsequently obtained samples.

'033 Patent Claim Language

Infringement Support




Source: Kurtz, Extended Fig. 10d.

The results of the additional tracking and whether the PVs were observed or not in the subsequently obtained plasma sample may be reported in a biomedical report.

'033 Patent Claim Language


Infringement Support







Source: ASCO Meeting 2021: Abstract #8518: Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer, David M. Kurtz, et al. (hereinafter "Kurtz Poster," attached hereto as Exhibit K).


Additionally, the Foresight website indicates the use of time-based reporting and monitoring:


'033 Patent Claim Language	Infringement Support
	 Source: https://foresight-dx.com/technology
14. The method of claim 13, wherein said first time point and said additional time point are at least 1 week apart, or more.	The Foresight Diagnostic Solid Tumor Recurrence test applies the plasma testing at multiple time points that are at least one week apart or more. For example, the Kurtz Poster shows detection of ctDNA in plasma by PhasED-Seq at multiple timepoints up to 9 months after the start of treatment.


'033 Patent Claim Language	Infringement Support
	 Source: Kurtz Poster
15. The method of claim 13, wherein said first time point and said additional time point are at least 1 month apart, or more.	The Foresight Diagnostic Solid Tumor Recurrence test applies the plasma testing at multiple time points that are at least one month apart or more. For example, the Kurtz Poster shows detection of ctDNA in plasma by PhasED-Seq at multiple time points up to 9 months after the start of treatment.


'033 Patent Claim Language	Infringement Support																								
	Pretreatment Mass  Treatment Response  Biopsy confirmed recurrent disease  Tumor Fraction in Plasma <table border="1"><caption>Approximate data points from the graph</caption><thead><tr><th>Months From Start of Treatment</th><th>CAPP-Seq (Tumor Fraction)</th><th>PhasED-Seq (Tumor Fraction)</th><th>Tumor Volume (mL)</th></tr></thead><tbody><tr><td>0</td><td>10^{-2}</td><td>10^{-2}</td><td>95</td></tr><tr><td>1</td><td>ND</td><td>10^{-5}</td><td>85</td></tr><tr><td>2</td><td>ND</td><td>10^{-6}</td><td>75</td></tr><tr><td>5</td><td>ND</td><td>$10^{-5.5}$</td><td>45</td></tr><tr><td>8.5</td><td>$10^{-4.5}$</td><td>$10^{-4.5}$</td><td>55</td></tr></tbody></table> Source: Kurtz Poster.	Months From Start of Treatment	CAPP-Seq (Tumor Fraction)	PhasED-Seq (Tumor Fraction)	Tumor Volume (mL)	0	10^{-2}	10^{-2}	95	1	ND	10^{-5}	85	2	ND	10^{-6}	75	5	ND	$10^{-5.5}$	45	8.5	$10^{-4.5}$	$10^{-4.5}$	55
Months From Start of Treatment	CAPP-Seq (Tumor Fraction)	PhasED-Seq (Tumor Fraction)	Tumor Volume (mL)																						
0	10^{-2}	10^{-2}	95																						
1	ND	10^{-5}	85																						
2	ND	10^{-6}	75																						
5	ND	$10^{-5.5}$	45																						
8.5	$10^{-4.5}$	$10^{-4.5}$	55																						
16. The method of claim 13, wherein said additional time point is later than said first time point.	The Foresight Diagnostics Solid Tumor Recurrence test conducts a second sequencing assay on the second subset of nucleic acids generated from the plasma DNA sample obtained at subsequent times.																								


'033 Patent Claim Language	Infringement Support
	Pretreatment Mass Treatment Response Biopsy confirmed recurrent disease Tumor Fraction in Plasma Legend: CAPP-Seq (red circle), PhasED-Seq (blue circle), Tumor Volume (green square), Undetected (white circle). Horizontal dashed lines: CAPP-Seq Limit of Detection (red), PhasED-Seq Limit of Detection (blue). Shaded region: Immunotherapy (Months 2 to 8). Green square at Month 0: CRT. Source: Kurtz Poster.
19. The method of claim 1, wherein said subsequently obtained biological sample is a plasma sample.	The Foresight Diagnostics Solid Tumor Recurrence tests utilizes samples isolated from an individual's germline DNA, tumor biopsy DNA, and plasma DNA.


'033 Patent Claim Language	Infringement Support
	 The diagram, labeled 'b', illustrates a personalized medicine workflow. It begins with a red human figure. A horizontal timeline shows 'Diagnosis of malignancy' (black dot), 'Treatment' (orange bar), and 'Subsequent TIME POINT' (black dot). Below 'Diagnosis of malignancy', two DNA samples are shown: 'Germline DNA' (test tube) and 'Tumor biopsy DNA' (cell cluster). Below 'Subsequent TIME POINT', a 'Plasma DNA' sample (test tube) is shown, circled in red. The workflow proceeds through several steps: 'I-seq' (indicated by a blue arrow), 'WGS' (Whole Genome Sequencing, indicated by a yellow arrow), 'PV discovery' (Polymorphism discovery, indicated by a yellow arrow), and 'Personalized selector design' (indicated by a yellow arrow). The final step is 'Personalized PV monitoring' (indicated by a green arrow). The 'Personalized selector design' step leads to a 'Personalized selector sequencing' step, which then leads to 'Personalized PV monitoring'. The 'Personalized selector sequencing' step is also indicated by a green arrow. The 'Personalized PV monitoring' step is indicated by a green arrow. The 'Personalized selector design' step leads to a 'Personalized selector sequencing' step, which then leads to 'Personalized PV monitoring'. Source: Kurtz, Fig. 7b
21. The method of claim 1, wherein said one or more databases of polymorphisms comprises a biomedical database.	The database of polymorphisms used in the Foresight Diagnostics Solid Tumor Recurrence test is biomedical database:

'033 Patent Claim Language	Infringement Support
	b  Source: Kurtz, Fig. 7b The Foresight Diagnostics Solid Tumor Recurrence test tracks SNVs from a biomedical database as well:

'033 Patent Claim Language	Infringement Support
	 Source: https://foresight-dx.com/partnership
22. The method of claim 1, wherein said one or more polymorphisms are observed in a population of a single sample.	The polymorphisms in the Foresight Diagnostics Solid Tumor Recurrence test are observed in a population of a single sample:

'033 Patent Claim Language	Infringement Support
	 The diagram, labeled 'b', illustrates a clinical workflow. It begins with a red human figure. A horizontal timeline shows 'Diagnosis of malignancy' (black dot), 'Treatment' (orange bar), and 'Subsequent TIME POINT' (black dot). Below 'Diagnosis of malignancy', 'Germline DNA' (test tube) and 'Tumor biopsy DNA' (cell cluster) are shown. Below 'Subsequent TIME POINT', 'Plasma DNA' (test tube) is shown. Arrows lead from the DNA samples to sequencing steps: 'I-seq' (blue arrow) and 'WGS' (yellow arrow) lead to 'PV discovery' (circled in red). 'WGS' also leads to 'Personalized selector design' (circled in red). 'Plasma DNA' leads to 'Personalized selector sequencing' (green arrow) and then 'Personalized PV monitoring' (green arrow). A DNA double helix is shown between 'Personalized selector design' and 'Personalized selector sequencing'. Source: Kurtz, Fig. 7b
23. The method of claim 1, wherein said plurality of polymorphisms are based on or extracted from said one or more databases of polymorphisms and observed in said population, wherein said population comprises a plurality of samples	The polymorphisms in the Foresight Diagnostics Solid Tumor Recurrence test are based on or extracted from databases of polymorphisms and observed in a population of a plurality of samples:

'033 Patent Claim Language	Infringement Support												
	b  Source: Kurtz, Fig. 7b <table><tr><th>PhasED-Seq (Foresight Diagnostics)</th><th>Hybrid capture-based NGS</th><th>PVs, SNVs</th><th>Baseline: tumor or plasma MRD/monitoring: plasma</th><th>Tumor-informed</th><th>< 0.0001% TF</th></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr></table> Chen K et al., MolDiag&Ther 2021 Source: BloodPac annual meeting slides (BloodPac slides, attached hereto as Exhibit L); Chen, et al., Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors, MolDiag&Ther (2021) at Table 1 (hereinafter “Chen,” attached hereto as Exhibit M). In addition, the Foresight Diagnostics Solid Tumor Recurrence test tracks clinically relevant polymorphisms that are in genes with known biomedically interpretable	PhasED-Seq (Foresight Diagnostics)	Hybrid capture-based NGS	PVs, SNVs	Baseline: tumor or plasma MRD/monitoring: plasma	Tumor-informed	< 0.0001% TF						
PhasED-Seq (Foresight Diagnostics)	Hybrid capture-based NGS	PVs, SNVs	Baseline: tumor or plasma MRD/monitoring: plasma	Tumor-informed	< 0.0001% TF								

'033 Patent Claim Language	Infringement Support
	variants, wherein said plurality of polymorphisms are based on or extracted from one or more databases of polymorphisms, and are observed in a population of one or more samples:  Source: https://foresight-dx.com/partnership